526 related articles for article (PubMed ID: 25151851)
1. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study.
Virchow JC; Weuthen T; Harmer QJ; Jones S
Expert Opin Drug Deliv; 2014 Dec; 11(12):1849-57. PubMed ID: 25151851
[TBL] [Abstract][Full Text] [Related]
2. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
[TBL] [Abstract][Full Text] [Related]
3. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
Grant AC; Walker R; Hamilton M; Garrill K
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
[TBL] [Abstract][Full Text] [Related]
4. Usage and usability of one dry powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany.
Hantulik P; Wittig K; Henschel Y; Ochse J; Vahteristo M; Rytila P
Pneumonol Alergol Pol; 2015; 83(5):365-77. PubMed ID: 26378998
[TBL] [Abstract][Full Text] [Related]
5. Novolizer: how does it fit into inhalation therapy?
Magnussen H
Curr Med Res Opin; 2005; 21 Suppl 4():S39-46; discussion S47. PubMed ID: 16138944
[TBL] [Abstract][Full Text] [Related]
6. Assessment of satisfaction with different dry powder inhalation devices in Greek patients with COPD and asthma: the ANASA study.
Zervas E; Samitas K; Gaga M
Int J Chron Obstruct Pulmon Dis; 2016; 11():1845-55. PubMed ID: 27540287
[TBL] [Abstract][Full Text] [Related]
7. First-time handling of different inhalers by chronic obstructive lung disease patients.
Harb HS; Laz NI; Rabea H; Abdelrahim MEA
Exp Lung Res; 2020 Sep; 46(7):258-269. PubMed ID: 32614625
[No Abstract] [Full Text] [Related]
8. Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment.
Hawken N; Torvinen S; Neine ME; Amri I; Toumi M; Aballéa S; Plich A; Roche N
BMC Pulm Med; 2017 Jul; 17(1):99. PubMed ID: 28683805
[TBL] [Abstract][Full Text] [Related]
9. How many instructions are required to correct inhalation errors in patients with asthma and chronic obstructive pulmonary disease?
Takaku Y; Kurashima K; Ohta C; Ishiguro T; Kagiyama N; Yanagisawa T; Takayanagi N
Respir Med; 2017 Feb; 123():110-115. PubMed ID: 28137486
[TBL] [Abstract][Full Text] [Related]
10. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.
Azouz W; Chetcuti P; Hosker H; Saralaya D; Chrystyn H
BMC Pulm Med; 2015 May; 15():47. PubMed ID: 25927483
[TBL] [Abstract][Full Text] [Related]
11. Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD.
Svedsater H; Dale P; Garrill K; Walker R; Woepse MW
BMC Pulm Med; 2013 Dec; 13():72. PubMed ID: 24314123
[TBL] [Abstract][Full Text] [Related]
12. The clinical relevance of dry powder inhaler performance for drug delivery.
Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Crossover Trial Evaluating Patient Handling, Preference, and Ease of Use of the Fluticasone Propionate/Formoterol Breath-Triggered Inhaler.
Bell D; Mansfield L; Lomax M
J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):425-434. PubMed ID: 28683212
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
[TBL] [Abstract][Full Text] [Related]
15. Device-handling study of a novel breath-actuated inhaler, Synchrobreathe®, versus a pMDI.
Balamurugan S; Apte K; Singh BP; Deb AK; Deshmukh C; Modi K; Godse A; Dhar R; Lahiri KR; Singh V; Pandya H; Rajan S; Vaidya A; Gaur V; Gogtay J
Respir Med; 2020 Jan; 161():105707. PubMed ID: 32056719
[TBL] [Abstract][Full Text] [Related]
16. Inhaled drug delivery in the hands of the patient.
Lavorini F
J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):414-8. PubMed ID: 25238005
[TBL] [Abstract][Full Text] [Related]
17. Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD.
Schulte M; Osseiran K; Betz R; Wencker M; Brand P; Meyer T; Haidl P
J Aerosol Med Pulm Drug Deliv; 2008 Dec; 21(4):321-8. PubMed ID: 18823257
[TBL] [Abstract][Full Text] [Related]
18. Prospective evAluatIon foR inhalation devices in Greek patients with COPD and asthma: The PAIR study.
Karampitsakos T; Hillas G; Zervas E; Bakakos P; Stratakos G; Dimakou K; Manali E; Bouros D; Papiris S; Tzouvelekis A;
Pulm Pharmacol Ther; 2020 Feb; 60():101882. PubMed ID: 31881275
[TBL] [Abstract][Full Text] [Related]
19. Correct use and ease of use of a placebo dry powder inhaler in subjects with asthma and chronic obstructive pulmonary disease.
Feldman GJ; Galkin DV; Patel P; Collison KA; Sharma R
Chron Respir Dis; 2019; 16():1479973118815692. PubMed ID: 30789018
[TBL] [Abstract][Full Text] [Related]
20. Optimizing drug delivery in COPD: The role of inhaler devices.
Rogliani P; Calzetta L; Coppola A; Cavalli F; Ora J; Puxeddu E; Matera MG; Cazzola M
Respir Med; 2017 Mar; 124():6-14. PubMed ID: 28284323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
